Breaking Down Sunshine Biopharma, Inc. (SBFM) Financial Health: Key Insights for Investors

Are you keeping a close watch on pharmaceutical stocks and wondering about the financial stability of Sunshine Biopharma Inc. (SBFM)? Despite a 45% surge in revenue, reaching $34.9 million in fiscal year 2024, the company's journey isn't without its complexities. While gross profit increased to $10.7 million, general and administrative expenses also rose to $16.5 million. How do these figures impact the overall financial health, and what are the key factors influencing investor decisions? Dive in to uncover critical insights into SBFM's performance, including new drug launches, regulatory approvals, and ongoing research, to help you make informed investment choices.

Sunshine Biopharma, Inc. (SBFM) Revenue Analysis

A deep dive into Sunshine Biopharma, Inc.'s revenue streams reveals critical insights for investors. Understanding where the company's income originates, how it has changed over time, and the relative importance of each segment is essential for assessing its financial health and growth potential.

Based on the latest available information, Sunshine Biopharma, Inc.'s revenue streams can be broken down as follows:

• Primary Revenue Sources: Sunshine Biopharma, Inc. is focused on the research and development of oncology and antiviral drugs. As of the fiscal year 2024, the company's revenue is primarily derived from research and development activities.
• Year-over-Year Revenue Growth Rate: Examining historical trends in revenue growth provides valuable context. For instance, comparing revenue from 2023 to 2024 indicates the company's growth trajectory. However, it's important to note that as a development-stage company, revenue can be variable and heavily influenced by research grants, collaborations, and milestone achievements.
• Contribution of Different Business Segments to Overall Revenue: As of 2024, the company’s main focus is research and development in the pharmaceutical sector, particularly in oncology and antiviral therapies.
• Analysis of Any Significant Changes in Revenue Streams: Investors should monitor any shifts in Sunshine Biopharma, Inc.'s revenue streams. For example, new partnerships, successful clinical trials leading to licensing agreements, or changes in government regulations could significantly impact the company's financial performance.

For more detailed insights into the investors of Sunshine Biopharma, Inc., you can explore: Exploring Sunshine Biopharma, Inc. (SBFM) Investor Profile: Who’s Buying and Why?

To provide a clearer picture, here's a hypothetical revenue breakdown based on typical revenue sources for a development-stage pharmaceutical company:

It's crucial to recognize that these figures are illustrative. Investors should refer to Sunshine Biopharma, Inc.'s official financial statements and reports for accurate and up-to-date information on the company's revenue streams.

Sunshine Biopharma, Inc. (SBFM) Profitability Metrics

Analyzing Sunshine Biopharma, Inc.'s profitability involves examining several key metrics that provide insights into its financial health. These include gross profit, operating profit, and net profit margins. Additionally, observing trends in these metrics over time and comparing them against industry averages helps to assess the company's operational efficiency, particularly its cost management and gross margin trends.

As of the fiscal year 2024, detailed profitability figures and comparisons against industry standards are essential for a thorough evaluation. Accessing the most recent financial reports and industry benchmarks will provide a clear understanding of Sunshine Biopharma, Inc.'s current financial standing.

To gain more clarity of Sunshine Biopharma, Inc. (SBFM), you can check: Mission Statement, Vision, & Core Values of Sunshine Biopharma, Inc. (SBFM).

To effectively evaluate Sunshine Biopharma, Inc.'s financial health, consider the following factors:

• Gross Profit Margin: This indicates the efficiency of Sunshine Biopharma, Inc.'s production process. It is calculated as (Revenue - Cost of Goods Sold) / Revenue.
• Operating Profit Margin: This ratio reveals how much profit Sunshine Biopharma, Inc. makes from its operations before interest and taxes. It is calculated as Operating Income / Revenue.
• Net Profit Margin: This is the percentage of revenue that remains after all expenses, including taxes and interest, have been deducted. It is calculated as Net Income / Revenue.

Analyzing these margins over a period and comparing them with industry peers can highlight areas of strength and weakness in Sunshine Biopharma, Inc.'s financial performance. Here’s an example of how this data might be organized (Note: Since actual 2024 data may not be available, the following table is a hypothetical illustration):

Operational Efficiency: Evaluating how well Sunshine Biopharma, Inc. manages its costs is crucial. Declining operating losses could signal improved efficiency, but it's important to understand whether this is due to increased revenue, decreased costs, or a combination of both.

Sunshine Biopharma, Inc. (SBFM) Debt vs. Equity Structure

Understanding how Sunshine Biopharma, Inc. (SBFM) finances its operations and growth is crucial for investors. This involves analyzing the company's debt levels, debt-to-equity ratio, and its approach to balancing debt and equity financing. Here's a detailed look:

As of the fiscal year 2024, Sunshine Biopharma, Inc. (SBFM) showcases the following debt profile:

• Long-term Debt: Specific figures for long-term debt were not found in the provided search results for the fiscal year 2024.
• Short-term Debt: Similarly, the exact short-term debt figures for 2024 were not available in the search results.

Given the absence of precise debt figures, a comprehensive debt-to-equity ratio calculation and comparison to industry standards cannot be accurately provided. This information is typically derived from the company's financial statements.

Recent activities such as debt issuances, credit ratings, or refinancing can significantly impact a company's financial structure. However, specific details regarding Sunshine Biopharma, Inc.'s (SBFM) recent debt-related activities were not available in the search results for 2024.

Balancing debt and equity is vital for funding growth. Without current specific data, it’s challenging to assess Sunshine Biopharma, Inc.'s (SBFM) strategy in this area. Generally, companies use a mix of both to optimize financial leverage and manage risk. Equity financing can reduce debt burden but may dilute ownership, while debt financing can offer tax advantages but increases financial risk.

For detailed insights, refer to the full analysis: Breaking Down Sunshine Biopharma, Inc. (SBFM) Financial Health: Key Insights for Investors

Sunshine Biopharma, Inc. (SBFM) Liquidity and Solvency

Assessing Sunshine Biopharma, Inc.'s (SBFM) liquidity involves examining its ability to meet short-term obligations, which is crucial for investors to gauge its financial health. Key metrics include current and quick ratios, working capital trends, and cash flow statements.

The current ratio and quick ratio are essential indicators of a company's liquidity position. For the fiscal year 2024, Sunshine Biopharma, Inc.'s current ratio and quick ratio provide insights into its ability to cover short-term liabilities with its current assets. A current ratio of above 1 suggests that the company has more current assets than current liabilities, indicating good liquidity. The quick ratio, which excludes inventory from current assets, offers a more conservative view of liquidity.

Analysis of working capital trends is also vital. Working capital, calculated as current assets minus current liabilities, indicates the company's operational liquidity. Monitoring the trend of working capital over several periods helps investors understand whether the company's short-term financial health is improving or deteriorating. Consistent positive working capital suggests a stable liquidity position.

Cash flow statements provide a comprehensive view of Sunshine Biopharma, Inc.'s cash inflows and outflows, categorized into operating, investing, and financing activities. Analyzing these cash flow trends helps assess the company's ability to generate cash from its core business operations. Positive cash flow from operations indicates that the company is generating sufficient cash to fund its operations and growth. Trends in investing and financing cash flows provide insights into the company's capital expenditures and funding activities.

Potential liquidity concerns or strengths can be identified through a thorough analysis of these financial metrics. For instance, a declining current ratio or negative operating cash flow may signal liquidity issues, while a consistently strong current ratio and positive operating cash flow indicate a solid liquidity position. Investors should also consider any significant changes in working capital trends or unusual cash flow patterns that may warrant further investigation.

For more insights into the company's strategic direction, you might find this resource helpful: Mission Statement, Vision, & Core Values of Sunshine Biopharma, Inc. (SBFM).

Sunshine Biopharma, Inc. (SBFM) Valuation Analysis

Determining whether Sunshine Biopharma, Inc. (SBFM) is overvalued or undervalued requires a multifaceted approach, incorporating various financial ratios, stock performance analysis, and analyst opinions. Here's a breakdown of key valuation indicators:

Valuation Ratios

Valuation ratios provide a snapshot of how the market values Sunshine Biopharma, Inc. relative to its earnings, book value, and sales. Some of the key ratios to consider include:

• Price-to-Earnings (P/E) Ratio: For 2025, the estimated P/E ratio is 1.69x. However, the P/E ratio for 2026 is not available.
• Price-to-Book (P/B) Ratio: As of March 31, 2025, the P/B Ratio is 0.16.
• Enterprise Value-to-EBITDA (EV/EBITDA) Ratio: Not directly mentioned in the provided snippets, but Enterprise Value is fluctuating between 3.42M and 43.82M.
• EV/Sales Ratio: The estimated EV/Sales ratio for 2025 is 0.05x.

Stock Price Trends

Analyzing the stock price trends helps to understand market sentiment and historical performance. Here’s an overview of Sunshine Biopharma, Inc.'s stock price trends:

• Recent Price: As of April 18, 2025, the stock price is around $1.235.
• 52-Week Range: The 52-week high is $49.00, while the 52-week low is $1.17 (as of April 18, 2025).
• 1-Year Return: The stock has a 1-year return of -96.54%.
• 3-Year Return: The stock has a 3-year return of -99.98%.
• 7-Day Price Movement: The stock has moved down by -10.3% in the last 7 days (as of April 18, 2025).

Additional Data Points

Key statistics as of April 18, 2025:

• Market Capitalization: $4.4M
• Revenue (TTM): $34.9M
• EBITDA: $-5.6M
• Earnings Per Share (EPS): $-7.32

Analyst Consensus

Analyst ratings provide insights into the perceived future performance of the stock:

• Consensus Rating: Strong Buy.
• Analyst Recommendation: Based on analyst ratings, approximately 85% recommend a Buy, and 14% recommend a Hold.
• Price Target: The analyst price target for Sunshine Biopharma, Inc. (SBFM) in 2025 is $15.
• 1 Year Target: $300.00.

For more insights into the company's strategic direction, you might find this resource helpful: Mission Statement, Vision, & Core Values of Sunshine Biopharma, Inc. (SBFM).

Sunshine Biopharma, Inc. (SBFM) Risk Factors

Investing in Sunshine Biopharma, Inc. (SBFM) involves navigating a complex landscape of risks, both internal and external. These risks can significantly impact the company’s financial health and should be carefully considered by investors. Here’s an overview of key risk factors:

Industry Competition: The pharmaceutical industry is highly competitive. Sunshine Biopharma, Inc. (SBFM) faces competition from established pharmaceutical companies with greater financial, technical, and marketing resources. Smaller companies may find it difficult to compete with larger companies. Intense competition can lead to price pressures, reduced market share, and decreased profitability.

Regulatory Changes: The development, manufacturing, and marketing of pharmaceutical products are subject to extensive regulation by governmental authorities, including the U.S. Food and Drug Administration (FDA) and similar agencies in other countries. Changes in regulations or the introduction of new laws can increase compliance costs, delay product approvals, and limit the company’s ability to market its products. Clinical trials can be delayed or halted due to regulatory concerns.

Market Conditions: Unfavorable market conditions, such as economic downturns or changes in healthcare spending, can negatively affect the demand for Sunshine Biopharma, Inc.'s (SBFM) products. Changes in consumer preferences or the emergence of new treatment options can also impact the company’s sales and profitability. Market volatility and uncertainty can make it difficult to forecast future performance.

Operational Risks:

• Reliance on Key Personnel: The success of Sunshine Biopharma, Inc. (SBFM) depends, in part, on the contributions of its key executives and scientific personnel. The loss of key personnel or the inability to attract and retain qualified employees could adversely affect the company’s operations.
• Manufacturing and Supply Chain Risks: Disruptions in the manufacturing process or supply chain, such as raw material shortages or quality control issues, can delay product development and commercialization. Dependence on third-party manufacturers can increase these risks.
• Intellectual Property Protection: The company’s ability to protect its intellectual property, including patents and trade secrets, is crucial for maintaining a competitive advantage. Infringement of intellectual property rights or the failure to obtain and maintain adequate protection can harm the company’s business.

Financial Risks:

• Limited Operating History: As a development-stage company, Sunshine Biopharma, Inc. (SBFM) has a limited operating history and a history of losses. The company has not yet generated significant revenue from product sales and may never achieve profitability.
• Need for Additional Financing: The development of pharmaceutical products is capital-intensive. Sunshine Biopharma, Inc. (SBFM) will require additional financing to fund its research and development activities, clinical trials, and commercialization efforts. The company may not be able to obtain financing on favorable terms or at all, which could delay or halt its development programs.
• Dilution Risk: The company may issue additional shares of common stock to raise capital, which could dilute the ownership interests of existing shareholders. The issuance of new shares could also depress the market price of the company’s stock.

Strategic Risks:

• Product Development Risks: The development of pharmaceutical products is a lengthy and uncertain process. Clinical trials may fail to demonstrate the safety and efficacy of the company’s product candidates, which could result in significant delays or the abandonment of development programs.
• Commercialization Risks: Even if a product is approved for marketing, there is no guarantee that it will be commercially successful. Factors such as market acceptance, competition, and pricing can affect the product’s sales and profitability.
• Acquisition and Integration Risks: Sunshine Biopharma, Inc. (SBFM) may pursue acquisitions or strategic alliances to expand its product pipeline or market presence. These transactions involve risks, such as the integration of acquired businesses, the management of strategic alliances, and the diversion of management’s attention.

Mitigation strategies or plans (if available): Reviewing Sunshine Biopharma, Inc.'s (SBFM) filings with the Securities and Exchange Commission (SEC) can provide insights into the company's specific risk disclosures and mitigation strategies. These filings, including Form 10-K (annual report) and Form 10-Q (quarterly report), outline the risks the company believes are most likely to affect its business and financial condition.

Here is more information: Breaking Down Sunshine Biopharma, Inc. (SBFM) Financial Health: Key Insights for Investors

Sunshine Biopharma, Inc. (SBFM) Growth Opportunities

For Sunshine Biopharma, Inc. (SBFM), evaluating future growth prospects requires a close look at several key factors. These include product innovation, potential market expansions, strategic initiatives, and the competitive landscape.

Analysis of key growth drivers:

• Product Innovations: Sunshine Biopharma focuses on developing oncology and antiviral drugs. Their primary growth driver involves advancing these drugs through clinical trials and securing regulatory approvals, particularly for their lead compound, Adva-27a.
• Market Expansion: Expanding into new geographical markets and targeting specific patient populations could significantly drive revenue growth.
• Acquisitions: As of now, there are no recent acquisitions.

Future revenue growth projections and earnings estimates are subject to several uncertainties, inherent to the biotechnology industry. These uncertainties include:

• Clinical trial outcomes
• Regulatory approvals
• Market acceptance of new drugs
• The ability to secure partnerships and funding

Strategic initiatives and partnerships that may drive future growth:

• Strategic Collaborations: Forming partnerships with other pharmaceutical companies or research institutions can accelerate drug development and broaden market reach.
• Funding and Investments: Securing additional funding through grants, equity offerings, or debt financing is crucial for supporting ongoing research and clinical trials.

Sunshine Biopharma faces significant competition from established pharmaceutical companies and other biotech firms developing similar treatments. A competitive advantage could be achieved through:

• Unique Drug Mechanisms: If Adva-27a has a novel mechanism of action or demonstrates superior efficacy and safety compared to existing treatments, it could gain a competitive edge.
• Intellectual Property: Strong patent protection for its drug candidates is essential for maintaining exclusivity and preventing generic competition.
• Orphan Drug Designation: Receiving orphan drug designation for specific indications can provide regulatory advantages and market exclusivity.

For more detailed insights, you can read the full analysis here: Breaking Down Sunshine Biopharma, Inc. (SBFM) Financial Health: Key Insights for Investors